CD19 and acute lymphoblastic leukemia: In fact, TCR T-cells against NY-ESO-1 positive synovial cell sarcoma and melanoma showed great potential in 2010 even before the first successful case that CD19 CAR T-cell cured an Acute Lymphocytic Leukemia (ALL) patient in 2013, which indicated the anti-solid tumor efficacy of engineered T-cell therapies (32).